SUNRISE CONSULTING (OTC: SNRS)
"Up 191.67% on Thursday"

Detailed Quote: http://www.otcpicks.com/quotes/SNRS.php

Sunrise Consulting Group, Inc. CEO Raymond Chin, has been based in Hong Kong for the last 10 years and has established relationships with Chinese Companies that would like to go public and be listed on US exchanges such as (OTC.PK, OTC.BB, NASDAQ, AMEX, & NYSE). These companies are mostly from mainland China and Hong Kong, with contacts also in Laos, Vietnam, Malaysia, Australia and others in the Pacific Rim & Southeast Asia. The company's goal is to become the premier Investment Banking Firm servicing small to medium sized companies in China and throughout Asia. Management has had success with consulting with public companies in the United States as well.

SNRS News:

January 3 - Sunrise Consulting Group, Inc. Signs Letter of Intent With Cao Tian Iron Ore Mines, Hunan Province, China

Sunrise Consulting Group, Inc. (OTC: SNRS), signed a Letter of Intent with Cao Tian Iron Ore Mines, ZhuZhou City, Hunan Province, PRC "CHINA" for the concession rights to mine this particular area of that region for at least 30 years. The letter sets forth the basic terms and conditions under which both parties have agreed to.

Sunrise Consulting Group, Inc. will issue 1 million shares of preferred stock to own 100% of the mining rights when signing the final agreement. These shares will have guaranteed buyback options within 24 months at $1.00 USD per share. Total buyback will be $1,000,000 USD.

This particular parcel of land stretches to an astounding 3 square miles and the mountain has an estimated 3 million tons of Iron Ore that can be mined over the next 30 years. The company plans to rapidly move forward in accordance with terms and conditions set forth in the proposed agreement (LOI).

BLACK DRAGON RESOURCE COMPANIES (OTC: BDGR)
"Up 85.71% on Thursday"

Detailed Quote: http://www.otcpicks.com/quotes/BDGR.php

Black Dragon Resource Companies, Inc. engages in the acquisition, development, production, and sale of oil and gas, and natural gas properties in the United States. It produces oil and natural gas from marginal stripper wells, whose production has slowed to 1/2 barrels of crude oil per day or less. The company was incorporated in 1996 as Vita Health, Inc. and changed its name to Vita Warehouse Company, Inc. in 1999. Further, it changed its name to Texas Diversified Distributors, Inc. in 2001; to Black Dragon Resource, Inc. in February 2004; and to Black Dragon Resource Companies, Inc. in December 2004. Black Dragon Resource Companies, Inc. is headquartered in Oil City, Louisiana.

BDGR News:

January 3 - Black Dragon Announces Significant Further Progress on the Joint Venture Funding Negotiations

On January 2, 2008, Mr. Joe Lanza, President of Black Dragon Resource Companies, Inc. (OTC: BDGR) announced that negotiations with a Joint Venture Funding Partner, as previously announced last week, were close to being completed.

Mr. Lanza reiterated that the Funding Joint Partner has agreed to provide the Joint Venture with a significant investment of at least $100,000,000. He added that the Joint Venture Partner had just confirmed to its satisfaction that the Company's oil and gas reserves have a value of at least $2.7 billion dollars and that it was prepared to move forward with the transaction, subject to finalization of its audit, which should be completed within a week.

Mr. Lanza also reported that the Joint Venture Partner and the Company had agreed in principle to all terms of the Joint Venture Agreement, the completion of which is now subject only to Counsel's review.

Further, and perhaps most significant, Mr. Lanza reported that he had met with the proposed new management team who, according to Mr. Lanza, has the extensive experience in both oil and gas technology and in production management to ensure the success of the Joint Venture and the full and proper development of Black Dragon's extensive resources.

Mr. Lanza concluded by stating that he was most impressed with the proposed management team and upon the Funding of the Joint Venture and the finalization of all details of the Joint Venture that he believed his goal for the Company would have been realized and that he would promptly resign. All Black Dragon shareholders, he concluded, will be greatly benefited by the new Joint Venture structure, and with the expansion of Black Dragon operations, which could only increase shareholder value.

Management believes that all details of the Joint Venture will be finalized prior to the Annual Meeting on January 16, 2008, so that the matter could be considered by the Stockholders at that time.

INTERNATIONAL POWER GROUP (OTCBB: IPWG)
"Up 80.00% on Thursday"

Detailed Quote: http://www.otcpicks.com/quotes/IPWG.php

International Power Group, Ltd. engages in the construction and management of waste disposal plants in the United States. It primarily intends to build and operate waste-to-energy facilities to process solid and hazardous wastes by incineration. International Power Group, through its subsidiary, also offers waste disposal services. The company was founded in 1998 and is based in Celebration, Florida.

IPWG News:

January 3 - International Power Group Egypt, Ltd. Concludes Royalty Agreements with Two Egyptian Companies

International Power Group Egypt, Ltd. (“IPWG Egypt”), a subsidiary of International Power Group, Ltd. (OTCBB: IPWG), announced that it has consummated royalty agreements with Egypt Rubber, Ltd. (ERL) and the LOL Group (LOL) — two companies with considerable expertise in the waste oil and used tire recycling fields.

Louis D, Garcia, Chief Financial Officer of IPWG Egypt, stated, “These agreements are in furtherance of the August 2007 Memorandum of Understanding and Cooperation Protocol Agreement between the Egyptian government and IPWG Egypt’s principal shareholders. ERL will be constructing and operating a state-of-the-art tire recycling plant in Alexandria, Egypt, and LOL will be taking over from the Egyptian government operations of an existing waste oil recycling facility in Alexandria, Egypt. ERL and LOL already have in place agreements for the supply of waste oil and used tires to their plants, as well as orders for all of the recycled lube oil and rubber they will be producing. IPWG Egypt will receive a five percent (5%) royalty from both ERL and LOL for consulting and business development services.”

EARTH BIOFUELS INCORPORATED (OTCBB: EBOF)
"Up 34.88% on Thursday"

Detailed Quote: http://www.otcpicks.com/quotes/EBOF.php

Earth Biofuels, Inc. engages in the production, distribution, and sale of renewable fuels consisting of biodiesel, ethanol, and liquid natural gas, with a focus on biodiesel fuel, in the United States. It produces pure biodiesel fuel (B100) through the utilization of vegetable oils, such as soy and canola oil as raw material for sale directly to wholesale distributors; and as a blend stock to make B20 biodiesel primarily in Oklahoma and Texas. Earth Biofuels distributes petroleum/biodiesel blended fuel, such as B20 through wholesale distributors, truck stops, and fueling stations. The company also produces and distributes liquefied natural gas for municipal and commercial fleet customers primarily in Arizona and California, through its subsidiary, Earth LNG, Inc. In addition, Earth Biofuels has the exclusive license to sell and distribute BioWillie-branded biofuels. The company is headquartered in Dallas, Texas. Earth Biofuels, Inc. operates as a subsidiary of Apollo Resources International, Inc.

EBOF News:

January 3 - Earth Biofuels Subsidiary Receives Renewable LNG Output from Landfill Project

Earth Biofuels, Inc. (OTCBB: EBOF) announced that its subsidiary, Applied LNG Technologies, Inc. (“ALT”), has begun receiving regular deliveries of the output of renewable liquefied natural gas (“LNG”) produced from a landfill site in Orange County, California.

Per the terms of a prior agreement, ALT has the first right to purchase one hundred percent of the nameplate capacity (5,000 gallons per day) production of the LNG facility which is owned by a wholly-owned subsidiary of Prometheus Energy Company at the Frank R. Bowerman Landfill. ALT markets the LNG to the Orange County Transportation Authority.

ALT’s Vice President of Operations, Kevin Markey, said, “We are excited to incorporate renewable LNG from landfill gas into our growing California market. The demand for clean, transportation-grade LNG in California has never been higher.”

Prometheus’ Chief Operating Officer, Earl Franklin, added, “We are proud to have the first LNG production facility of its kind in operation and look forward to growing our relationship with ALT.”

Solid waste landfills produce a 50% methane gas as a result of the decomposition of organic materials within the landfill. The Bowerman production facility is the first of its kind in the U.S. to commercially produce renewable vehicle-grade LNG from landfill gas.

Transportation grade LNG helps companies meet strict emission standards in the state of California. Vehicles fueled by the transportation grade LNG produce approximately one-sixth of the nitrous oxides (NOx) and up to 15 percent less greenhouse gases than comparable petroleum diesel fueled vehicles.

UREX ENERGY CORPORATION (OTCBB: URXE)
"Up 33.33% on Thursday"

Detailed Quote: http://www.otcpicks.com/quotes/URXE.php

Urex Energy Corp., an exploration stage company, engages in the acquisition and exploration of uranium properties in Argentina and New Mexico. It holds interest in the Rio Chubut property comprising of 170,000 hectares located in the Chubut Province of Patagonia, southern Argentina; and the La Jara Mesa Extension Uranium property consisting of 137 unpatented mining claims of approximately 2,740 acres in Grants Mining District, Cibola County, New Mexico. The company was founded in 2002. It was formerly known as Lakefield Ventures, Inc. and changed its name to Urex Energy Corp. in 2006. Urex Energy is headquartered in Reno, Nevada.

URXE News:

January 3 - Urex Energy Corporation Reports Results from Airborne Geophysical Survey in Argentina

Urex Energy Corporation (OTCBB: URXE) (the “Company” or “Urex”) reports that New-Sense Geophysics Ltd. has completed 50% of a fixed wing aeromagnetic/radiometric survey over Urex’s Argentine properties within the Cerro Solo claim block.

Field geologic teams in December visited Urex’s Cerro Solo claim group to ground truth uranium anomalies identified by the airborne survey. The ground truthing process consists of the physical examination of rock outcrops and soils by geologists with a Gamma ray detecting instrument called a scintilometer or spectrometer. A scintilometer measures only total Gamma ray counts (radioactivity) whereas a Gamma ray spectrometer distinguishes Gamma radiation from specific elemental sources like uranium, thorium, and potassium. Field examinations confirm that the airborne defined uranium anomalies correlate to radioactive rock outcrops that measured up to 65,000 counts-per-second with a peak value of 12,490 parts per million uranium or 1.47 wt. % U3O8 as measured on a hand held Super Spec RS 125 Spectrometer manufactured by Radiation Solutions Inc. Uranium/Thorium ratio averages 11 to 1 for the rocks measured.

Conglomerate and sandstone rock samples taken from outcrops have been sent to American Assay Laboratories Inc. of Sparks, Nevada, for analysis of uranium and other elements using XRF method (X-ray fluorescence). All chemical assay results are pending.

Field mapping and ground truthing continues on the Company’s Cerro Solo area claims in preparation for a drilling program which is expected to start in February given drill rig availability.

Readers are cautioned that uranium assay results measured with a hand held Gamma ray spectrometer are only indicative of anomalous uranium content. Chemical assays are more reliable and should be used when evaluating rocks for the content of uranium.

PHYTOMEDICAL TECHNOLOGIES (OTCBB: PYTO)
"Up 27.59% on Thursday"

Detailed Quote: http://www.otcpicks.com/quotes/PYTO.php

PhytoMedical Technologies, Inc., together with its wholly owned subsidiaries, operates as an early stage research-based biopharmaceutical company. It focuses on the identification, acquisition, development, and commercialization of plant-derived pharmaceutical and nutraceutical compounds targeting cachexia, obesity, and diabetes. The company develops BDC-03, a plant derived compound that has capacity to decrease the deposition of fat and lower cholesterol. Additionally, through a cooperative research and development agreement, PhytoMedical engages in synthesizing the active components of various polyphenolic compounds found in cinnamon bark and characterizing their beneficial health effects in cell cultures systems, animals, and humans. The company, formerly known as Enterprise Technologies, Inc., was founded in 1986 and changed its name to PhytoMedical Technologies, Inc. in 2004. PhytoMedical Technologies is headquartered in Princeton, New Jersey.

PYTO News:

January 3 - PhytoMedical's Anti-Cancer Compound Effective at Killing Brain Cancer Cells

Novel Class of Patented Anti-Cancer Compounds Demonstrates Significant Ability to Kill Human Glioblastoma (Brain) Cancer Cells, an Extremely Resistant and Often Fatal Strain of Cancer

PhytoMedical Technologies, Inc. (OTCBB: PYTO) (FWB: ET6), announced that research outcomes from ongoing in vitro studies of the Company’s sponsored anti-cancer compounds have successfully demonstrated the ability to kill a strain of human brain cancer cells which is otherwise highly-resistant to currently available drugs.

Led by Dartmouth College researcher Dr. Gordon Gribble, researchers have determined that, one of several patented “bis-intercalator” anti-cancer compounds being developed by PhytoMedical has achieved a 50% or greater cancer cell kill rate at a minimum concentration in studies of the SF-295 strain of human glioblastoma (brain) cancer cells — a significant outcome, given these brain cancer cells’ drug-resistant nature.

“The outstanding results of this human cancer cell study is an extremely important step towards finding a potential solution for treating glioblastoma, an often fatal form of cancer,” commented Greg Wujek, President, CEO of PhytoMedical Technologies, Inc. “The demonstrated cytotoxic effects of this unique patented compound on such a resistant strain of cancer has given us the confidence to move forward in our research and improve upon the concept of bis-intercalation and the promise it holds for the control of cancer.”

In important in vitro experiments, researchers tested several variations of patented bis-intercalator compounds. These compounds have the unique capability to “intercalate” or insert their anti-cancer molecules inside DNA sites of specific cancer cells, thereby preventing the ability of the cancer cells to replicate and ultimately forcing their death.

“We are very happy,” says Alla Kan Director of Dartmouth’s Technology Transfer Office, “that we found a good partner to help us bring these powerful new drugs claimed in Dartmouth College issued patent #6,187,787 to the patient as this is an ultimate goal of our office, to utilize research taking place in our laboratories for the public good.”

Among several compounds tested in vitro against an often fatal strain of human glioblastoma (brain) cells, researchers have identified a high performance compound which requires the least concentration in order to achieve a 50% or greater cancer cell kill rate. This strong activity against glioblastoma cancer cells is a significant achievement given these cells’ strong resistance to currently available anticancer drugs such as Lomustine, Carmustine, Nitrosourea, Hydroxyurea, and Procarbazine.

PhytoMedical’s Cancer Research: Killing Cancer’s DNA

PhytoMedical is developing a novel class of patented anti-cancer agents that have a ‘cytotoxic’ or poisonous affinity for cancer cells and are designed to bind more tightly to cancer cell DNA than many conventional anticancer drugs by a process called bis-intercalation or “double binding,” much like a molecular staple. Because the DNA is the blueprint of life for the cancer cell, such binding stops the replication of the DNA, which prevents the growth of the cancer cell and it dies.

DNA is present in the nucleus of every cell of all living organisms, which are constantly dividing through a process in which the DNA in the nucleus of the original cell replicates itself to be present in the nuclei of the two new (“daughter”) cells. If this replication cannot occur, the cell will die and the organism will eventually stop growing and die. Cancer is characterized by the development of abnormal cells that divide uncontrollably and have the ability to infiltrate and destroy normal body tissue.

At present, anticancer molecules designed to block the replication of DNA do so through “intercalation,” a mechanism in which the drug inserts itself between one set of adjacent base pairs of the DNA. PhytoMedical believes a more effective anticancer strategy is to design molecules (“bis-intercalators”) that can intercalate simultaneously at two DNA sites, thus further increasing the binding between the drug and the DNA of specific cancer cells in order to stop their replication and ultimately resulting in the death of the cancer cell.